Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 29,900 shares, a growth of 864.5% from the July 15th total of 3,100 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 16,500 shares, the short-interest ratio is currently 1.8 days.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of Evogene in a report on Tuesday, August 6th. They issued a “sell” rating for the company.
Read Our Latest Analysis on EVGN
Evogene Trading Down 6.7 %
Evogene (NASDAQ:EVGN – Get Free Report) last announced its earnings results on Thursday, May 23rd. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%. The company had revenue of $4.19 million during the quarter.
Hedge Funds Weigh In On Evogene
A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its holdings in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) by 30.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
See Also
- Five stocks we like better than Evogene
- Insider Trading – What You Need to Know
- Micron Stock Just Got Its Most Bullish Update Of The Year
- Roth IRA Calculator: Calculate Your Potential Returns
- How to Trade a Long Straddle When Expecting a Large Earnings Move
- What is a Secondary Public Offering? What Investors Need to Know
- Is Qualcomm the Next AI-Powered Millionaire-Maker Stock?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.